Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Oramed Pharmaceuticals Inc. (ORMP)

3.8550 -0.1750 (-4.35%)
As of 2:04:16 PM EDT. Market Open.
Trade ORMP on Coinbase
Chart Range Bar
Loading chart for ORMP
  • Previous Close 4.0300
  • Open 4.0300
  • Bid 2.8800 x 200
  • Ask 4.9600 x 200
  • Day's Range 3.8300 - 4.0300
  • 52 Week Range 1.9800 - 4.2200
  • Volume 109,018
  • Avg. Volume 140,168
  • Market Cap (intraday) 155.92M
  • Beta (5Y Monthly) 1.25
  • PE Ratio (TTM) 2.57
  • EPS (TTM) 1.5000
  • Earnings Date (est.) May 15, 2026
  • Forward Dividend & Yield 0.25 (6.20%)
  • Ex-Dividend Date Jan 16, 2026
  • 1y Target Est 6.25

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.

oramed.com

--

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview: ORMP

Trailing total returns as of 4/29/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ORMP
45.09%
S&P 500 (^GSPC)
3.97%

1-Year Return

ORMP
77.47%
S&P 500 (^GSPC)
27.98%

3-Year Return

ORMP
82.17%
S&P 500 (^GSPC)
70.69%

5-Year Return

ORMP
61.96%
S&P 500 (^GSPC)
68.99%

Earnings Trends: ORMP

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue --
Earnings --

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

0
500K
1M
2M
2M

Analyst Insights: ORMP

View More

Analyst Price Targets

6.25
6.25 Average
3.8550 Current
6.25 High

Latest Rating

Date 9/9/2024
Analyst HC Wainwright & Co.
Rating Action Reiterates
Rating Neutral
Price Action --
Price Target --

Statistics: ORMP

View More

Valuation Measures

Annual
As of 4/28/2026
  • Market Cap

    163.00M

  • Enterprise Value

    37.93M

  • Trailing P/E

    2.69

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    85.47

  • Price/Book (mrq)

    0.82

  • Enterprise Value/Revenue

    18.96

  • Enterprise Value/EBITDA

    0.50

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    3,202.50%

  • Return on Assets (ttm)

    -4.88%

  • Return on Equity (ttm)

    37.10%

  • Revenue (ttm)

    2M

  • Net Income Avi to Common (ttm)

    63.24M

  • Diluted EPS (ttm)

    1.5000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    125.89M

  • Total Debt/Equity (mrq)

    0.41%

  • Levered Free Cash Flow (ttm)

    3.92M

Compare To: ORMP

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: ORMP

Fair Value

3.8550 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: